Bioheart, Inc (BHRT) Secures Worldwide Distribution Rights for Bioheart 3370
Bioheart, Inc is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Their lead product candidate is MyoCell®, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from the patient's body, for the purpose of improving cardiac function in chronic heart failure patients. In an unusual move, but one that shows how corporations can re-form themselves to the market and market conditions, Bioheart announced this week that it attained distribution rights…